Alireza Azani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alireza Azani has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anahid Bagheri Pour
Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Arash Salmaninejad
Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Faeze Ahmadi Beni
Department of Medical Genetics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
1 shared publication - Hassan Foroozand
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Hossein Gharedaghi
Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Malihe Sharafi
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 14 December 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70425
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Background: Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available therapeutic modalities for controlling UM. However, these techniques are associated with notable adverse effects and have limited efficacy. Therefore, there is a lack of sufficient and reliable therapies for UM, especially for advanced and metastatic UM forms. This review aims to summarize the clinical features and current therapies of UM and highlight recent progress in gene therapy approaches. Recent Findings: Significant developments in gene therapy have introduced multiple strategies for targeting UM. Gene silencing using siRNA and shRNA has shown efficacy in downregulating oncogenic pathways. CRISPR/Cas9‐based editing has enabled selective disruption of tumor‐promoting genes, sensitizing tumor cells to targeted inhibitors. Restoration of tumor‐suppressive miRNAs has reduced proliferation, migration, and invasion of UM cells in preclinical models. Suicide gene therapy has demonstrated potent cytotoxicity in xenografts. Moreover, oncolytic viruses and stem‐cell–associated delivery systems provide novel mechanisms for tumor‐selective gene expression and immune activation. Although challenges persist—such as delivery efficiency, immune responses, and genetic heterogeneity—ongoing innovations in vector design, non‐viral nanoformulations, and mutation‐guided therapies continue to enhance clinical feasibility. Conclusion: Gene therapy provides improved safety profiles and the possibility of tailored treatment strategies by integrating information on gene expression patterns and DNA alterations. In the future, gene therapy has the potential to improve the treatment of UM by targeting specific genetic mutations driving tumor growth and may offer new hope for patients with advanced stages of UM.
- 14 December 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (12) , e70425
Open AccessToward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Background: Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available therapeutic modalities for controlling UM. However, these techniques are associated with notable adverse effects and have limited efficacy. Therefore, there is a lack of sufficient and reliable therapies for UM, especially for advanced and metastatic UM forms. This review aims to summarize the clinical features and current therapies of UM and highlight recent progress in gene therapy approaches. Recent Findings: Significant developments in gene therapy have introduced multiple strategies for targeting UM. Gene silencing using siRNA and shRNA has shown efficacy in downregulating oncogenic pathways. CRISPR/Cas9‐based editing has enabled selective disruption of tumor‐promoting genes, sensitizing tumor cells to targeted inhibitors. Restoration of tumor‐suppressive miRNAs has reduced proliferation, migration, and invasion of UM cells in preclinical models. Suicide gene therapy has demonstrated potent cytotoxicity in xenografts. Moreover, oncolytic viruses and stem‐cell–associated delivery systems provide novel mechanisms for tumor‐selective gene expression and immune activation. Although challenges persist—such as delivery efficiency, immune responses, and genetic heterogeneity—ongoing innovations in vector design, non‐viral nanoformulations, and mutation‐guided therapies continue to enhance clinical feasibility. Conclusion: Gene therapy provides improved safety profiles and the possibility of tailored treatment strategies by integrating information on gene expression patterns and DNA alterations. In the future, gene therapy has the potential to improve the treatment of UM by targeting specific genetic mutations driving tumor growth and may offer new hope for patients with advanced stages of UM.